Acadian Asset Management
SPRY icon

Acadian Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Acadian Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,009
Closed -$58K – 2131
2024
Q3 		$58K Buy
+4,009
New +$47.7K ﹤0.01% 1758
2022
Q2 		– Sell
-39,720
Closed -$139K – 1845
2022
Q1 		$139K Sell
39,720
-38,914
-49% -$169K ﹤0.01% 1290
2021
Q4 		$522K Buy
+78,634
New +$639K ﹤0.01% 999

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Acadian Asset Management's SPRY Position: Q4 2024 in Review

Acadian Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 4,009 shares — an estimated $58K sold.

Acadian Asset Management first reported a position in SPRY in Q4 2021 and held it in 3 quarters. The position peaked at $522K in Q4 2021. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • Acadian Asset Management reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 4,009 ARS Pharmaceuticals shares in Q4 2024, an estimated $58K.
  • Acadian Asset Management first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Acadian Asset Management's ARS Pharmaceuticals position peaked at $522K in Q4 2021.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.